Rezolute (RZLT) Income from Continuing Operations (2012 - 2026)
Rezolute (RZLT) reported Income from Continuing Operations of 20928000.0 for Q1 2026, up 13.68% on a YoY basis from 18409957.62 in Q1 2025, and up 17.2% sequentially from 25274000.0 in Q4 2025.
Rezolute (RZLT) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Rezolute (RZLT) has 15 years of Income from Continuing Operations data on file, last reported at 20928000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 13.68% year-over-year to 20928000.0; the trailing twelve-month figure through Mar 2026 stood at 163257000.0 (down 43.66% YoY), and the FY2025 full-year result was 164347000.0, down 105.04% from the prior year.
- Income from Continuing Operations climbed to 20928000.0 in Q1 2026, from 25274000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9985000.0 in Q3 2022 to a low of 92461000.0 in Q3 2025.
- A 5-year average of 23745588.24 and a median of 19843000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 27.66% in 2025, while the deepest fall reached 158.47% in 2025.
- Tracing RZLT's Income from Continuing Operations over 5 years: stood at 14141000.0 in 2022, then slipped by 0.68% to 14237000.0 in 2023, then plunged by 145.39% to 34936000.0 in 2024, then rose by 27.66% to 25274000.0 in 2025, then advanced by 17.2% to 20928000.0 in 2026.
- Business Quant data shows RZLT's Income from Continuing Operations at 20928000.0 in Q1 2026, 25274000.0 in Q4 2025, and 92461000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Rezolute | 518.12 Mn | 518.12 Mn | - | -20.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.93 Mn |
| Dec 31, 2025 | -25.27 Mn |
| Sep 30, 2025 | -92.46 Mn |
| Jun 30, 2025 | -24.59 Mn |
| Mar 31, 2025 | -24.24 Mn |
| Dec 31, 2024 | -34.94 Mn |
| Sep 30, 2024 | -35.77 Mn |
| Jun 30, 2024 | -18.69 Mn |
| Mar 31, 2024 | -19.84 Mn |
| Dec 31, 2023 | -14.24 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -10.03 Mn |
| Mar 31, 2023 | -20.21 Mn |
| Dec 31, 2022 | -14.14 Mn |
| Sep 30, 2022 | -9.99 Mn |
| Jun 30, 2022 | -11.71 Mn |
| Mar 31, 2022 | -11.45 Mn |
| Dec 31, 2021 | -12.84 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -6.66 Mn |